A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Prior treatment

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have taken any of the following within 90 days prior to screening
  • medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
  • dipeptidyl peptidase 4 (DPP-4) inhibitors, and
  • insulin
• Have had within 90 days prior to screening:
  • heart attack
  • stroke
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure
• Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Other illness

• Have type 1 diabetes
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

• Have type 2 diabetes
• Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
• Have a BMI of ≥27 kg/m2 at screening
• Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight